Analytical Data
-
Gene name
BCL11B
- Application
-
Alternative Names
B-cell CLL/lymphoma 11B (COUP-TF-interacting protein 2) (Radiation-induced tumor suppressor gene 1 protein) (hRit1) (BCL-11B) (CTIP2) (RIT1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9C0K0
-
Expression Region
387-823aa
-
Molecular Weight
53.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCL11B, a member of the BCL11 family of proteins, plays a crucial role in the regulation of gene expression during the development of the immune system and the central nervous system. It is predominantly expressed in T cells and certain neuronal lineages, indicating its involvement in lineage commitment and differentiation. Research has shown that BCL11B acts as a transcriptional repressor, modulating the expression of genes associated with T cell development and function. Dysregulation of BCL11B has been implicated in various diseases, including autoimmune disorders and cancers, highlighting its potential as a therapeutic target. Recent studies have focused on the creation of recombinant BCL11B proteins to elucidate its functional mechanisms and interactomes. By employing techniques such as mass spectrometry and co-immunoprecipitation, researchers aim to identify BCL11B's protein partners and understand how its interactions influence cellular processes. The establishment of a reliable recombinant BCL11B protein system not only facilitates structural and functional studies but also paves the way for drug development aimed at modulating its activity in pathological contexts. As the BCL11B research landscape continues to evolve, understanding its complex regulatory networks will enhance our comprehension of immune and neuronal development, providing insights into targeted therapies for related diseases.
